Developer docs
API playgroundTry for free, no card

Search company profiles

Nuclidium

Full company profile

uuid000yf62

Namestring
Nuclidium
Legal namestring
Nuclidium AG
Websiteurl
nuclidium.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Nuclidium AG is a clinical-stage biotechnology company headquartered in Basel, Switzerland with an R&D subsidiary in Munich, Germany, founded in 2017 by CEO Dr. Leila Jaafar-Thiel. The company develops copper-based radiopharmaceuticals for cancer diagnosis and therapy, built on its proprietary CuTrace™ platform which pairs Copper-61 (a 3.3-hour half-life positron emitter for PET diagnostics) with Copper-67 (a 2.58-day half-life beta-emitter for therapy) on the same targeting ligand, enabling true theranostics with identical biodistribution between diagnostic and therapeutic agents. Its pipeline comprises four programs: NU101/NuriPro (PSMA-targeted, metastatic castration-resistant prostate cancer), NU201/TraceNET (SSTR2 antagonist, metastatic breast cancer and neuroendocrine tumors), and Kalios (FAP inhibitor, breast and lung cancer), with Phase 1/2 results reported in 2025 and Phase 1/2a therapeutic trials planned for 2026.

The business model is pre-commercial: revenue is expected to be generated through sales of 61Cu-based diagnostic PET imaging agents and 67Cu-based therapeutic radiopharmaceuticals to hospital nuclear medicine departments, supplemented by licensing/royalty arrangements and a manufacturing/supply network. To de-risk commercialization and global distribution, Nuclidium has built a multi-region production footprint — cyclotron-based 61Cu production through PharmaLogic in the US and LinaThera in Medical Valley Forchheim, Germany — and entered a strategic partnership with Guerbet for manufacturing, clinical trial support and commercialization. The company raised approximately CHF 105 million (EUR ~115 million) in Series B financing (July 2025 plus May 2026 extension) from a syndicate including Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, Neva SGR and the EIB co-investment facility Aurea, supplemented by grants from Innosuisse and the European Innovation Council. Its go-to-market is enterprise field sales targeting major hospital systems and academic medical centers with nuclear medicine departments.

Short descriptiontext

Nuclidium AG is a clinical-stage Swiss radiopharmaceutical company developing copper-based theranostics (Copper-61 diagnostics and Copper-67 therapeutics on the CuTrace™ platform) for cancer indications including prostate, breast and neuroendocrine tumors, targeting hospital nuclear medicine departments globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
copper radiopharmaceuticals, cancer theranostics, targeted radiotherapy, PET imaging agents, precision oncology drugs
Industry1 code
PRIMARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Radiopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Radiopharmaceutical Products
TypeOne Time License
Description

NUCLIDIUM develops and commercializes copper-based radiopharmaceuticals for cancer diagnosis and treatment. Revenue will be generated through sales of diagnostic PET imaging agents (61Cu-based) and therapeutic radiopharmaceuticals (67Cu-based) to hospitals and nuclear medicine centers.

labiotech.eu
2Licensing and Partnership Agreements
TypeLicensing Royalties
Description

Strategic partnerships with companies like Guerbet and PharmaLogic for manufacturing, distribution, and clinical development support. May include milestone payments and royalties from licensed technology.

nuclidium.com
3Manufacturing and Supply Network
TypeManaged Services
Description

Revenue generated through global production and manufacturing network for diagnostics and therapeutics, serving hospital workflows with copper-based radiopharmaceuticals.

nuclidium.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1CuTrace
Description

Proprietary technology platform utilizing copper radionuclides combined with tumour-specific molecules for targeted radiotherapy and diagnostics

nuclidium.com
+5 more records
Core offering1 text field

Nuclidium AG is a clinical-stage biotechnology company that develops copper-based radiopharmaceutical theranostics for cancer diagnosis and treatment. Using its proprietary CuTrace™ platform, the company pairs Copper-61 (diagnostic) with Copper-67 (therapeutic) on identical tumor-targeting molecules, enabling true theranostic pairs for prostate, breast, neuroendocrine, and FAP-expressing tumors. Products are designed for cyclotron-based production without nuclear reactors and are supplied to hospitals and nuclear medicine centers globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 61Cu-NuriPro PET visualized additional lesions in 50% of patients not seen with 18F-piflufolastat (FDA-approved standard of care)
+4 more records
Product overview1 text field

Nuclidium is a clinical-stage radiopharmaceutical company pioneering next-generation copper-based radiotheranostics. The company's CuTrace platform enables true theranostics by combining copper isotopes (Copper-61 for diagnostics and Copper-67 for therapeutics) with tumor-specific targeting molecules. The pipeline includes: NU101 (NuriPro) for PSMA-positive metastatic castration-resistant prostate cancer, NU201 for metastatic breast cancer, TraceNET for neuroendocrine tumors, and Kalios for FAP-expressing epithelial tumors. Individual products include 61Cu-NuriPro and 61Cu-TraceNET diagnostics, along with their corresponding 67Cu therapeutics. The company operates in Switzerland and Germany with manufacturing partnerships in Europe and North America.

Product and service7 records
1NU101 / NuriPro
CategoryTheranostic Program
2NU201 / TraceNET
CategoryTheranostic Program
3Kalios
CategoryTheranostic Program
461Cu-NuriPro (61Cu-NODAGA-PSMA I&T)
CategoryDiagnostic Radiopharmaceutical
561Cu-TraceNET ([61Cu]Cu-NODAGA-LM3)
CategoryDiagnostic Radiopharmaceutical
667Cu-NuriPro
CategoryTherapeutic Radiopharmaceutical
767Cu-TraceNET
CategoryTherapeutic Radiopharmaceutical
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-10-21
Description

Phase 1 clinical trial site for 61Cu-NuriPro™ diagnostic in PSMA-positive prostate cancer patients. Dr. Gary Ulaner serves as Principal Investigator. Trial conducted at Hoag Molecular Imaging and Therapy Clinic, Newport Beach, California.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-13
Description

Collaboration partner in Oberfrankenstiftung-funded project for production facility and clinical development of radionuclide therapies in Bavaria.

3Klinikum Bayreuth
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-13
Description

Clinical collaboration partner in Oberfrankenstiftung-funded project for radionuclide therapy production and development.

nuclidium.com
4Erlangen University Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-13
Description

Academic partner in Oberfrankenstiftung-funded project for clinical development of radionuclide therapies.

nuclidium.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-05-22
Description

Strategic partnership for advancement of NUCLIDIUM's copper-based radiotheranostics. Guerbet provides access to global diagnostic imaging expertise, manufacturing network, and clinical trial capabilities. François Nicolas (SVP R&D) joined NUCLIDIUM Board as observer. Guerbet made strategic, non-exclusive investment.

6LinaThera
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-02-02
Description

Partnership for building state-of-the-art integrated manufacturing facility in Medical Valley Forchheim. LinaThera produces medical radionuclides in modularly expandable accelerator facility without nuclear reactors. Project supported by Oberfrankenstiftung funding (€400,000).

nuclidium.com
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-05-15
Description

Strategic collaboration for production and clinical supply of 61Cu in the United States. PharmaLogic manufactures radiopharmaceuticals at their facilities including Los Angeles, CA. NUCLIDIUM provides scientific know-how and proprietary technology. First product batch manufactured in 2023.

8University Hospital Basel
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-03-21
Description

Clinical collaboration for Phase 1 trial with TraceNET™ in neuroendocrine tumors. NETRF Investigator Award shared between NUCLIDIUM and USB. Prof. Melpomeni Fani leads as PI. Clinical-scale production process established at USB.

nuclidium.com
Strategic tierCoreTypeOthersAnnounced on2023-03-21
Description

NETRF Investigator Award recipient for Phase 1 trial with TraceNET™ in neuroendocrine tumors. Award aims to support innovative research to improve NET patient care.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Curium is a global radiopharmaceutical company producing diagnostic and therapeutic nuclear medicines, including PET tracers. Comparable as both a competitor and potential commercial partner for radiopharma distribution.

TypeDirect peer
Description

Telix commercializes Illuccix (Ga-68 PSMA-11) for PSMA PET imaging and is developing therapeutic radiopharmaceuticals. Direct competitor across the PSMA theranostic landscape with commercial-stage products.

TypeBroad incumbent
Description

Novartis commercializes Pluvicto (Lu-177 PSMA-617) and Locametz for mCRPC, directly competing with Nuclidium's NU101 program. As the established radioligand therapy leader with approved products and global launch infrastructure, Novartis represents the primary competitive benchmark.

TypeDirect peer
Description

Point Bio developed Lu-177 PSMA radioligand therapies for mCRPC and was acquired by Eli Lilly for $1.4B in 2024. Highly comparable as a PSMA radioligand developer and a benchmark for the exit opportunity Nuclidium's NU101 could pursue.

TypeBroad incumbent
Description

Bayer has invested in radiopharmaceuticals including Xofigo (Ra-223) and partnerships targeting PSMA and other radioligand therapies. As a broad incumbent pharma with significant radiopharma ambitions, Bayer represents both competitor and potential acquirer.

TypeDirect peer
Description

ITM is a radiopharmaceutical company developing therapeutic and diagnostic radioisotope-based products, including Lu-177-based compounds. Competes in the precision oncology radiopharma space with similar production and distribution infrastructure.

TypeDirect peer
Description

Lantheus commercializes Pylarify (18F-piflufolastat), the FDA-approved PSMA PET imaging agent that Nuclidium's 61Cu-NuriPro demonstrated superiority over in Phase 1 trials. Direct competitor in the diagnostic PSMA imaging market.

TypeBroad incumbent
Description

Bracco is an established diagnostic imaging company with a growing radiopharmaceutical portfolio. Overlaps with Nuclidium in molecular imaging agents and represents a potential commercial partner or acquirer for the diagnostic pipeline.

TypeDirect peer
Description

Ariceum develops SSTR2 antagonist-based radiopharmaceuticals (acquired from Ipsen), directly overlapping with Nuclidium's TraceNET SSTR2 program. Notably, Nuclidium's CMO Ben Pais previously led clinical development at Ariceum.

TypeEmerging player
Description

Radiopharm Theranostics is a clinical-stage radiopharma developing multiple radiotheranostic assets for oncology, with similar stage and pipeline breadth to Nuclidium. Directly comparable as a peer emerging radiotheranostic platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nuclidium

Radiopharmaceuticalsnuclidium.com

Nuclidium AG is a clinical-stage Swiss radiopharmaceutical company developing copper-based theranostics (Copper-61 diagnostics and Copper-67 therapeutics on the CuTrace™ platform) for cancer indications including prostate, breast and neuroendocrine tumors, targeting hospital nuclear medicine departments globally.

What Nuclidium does

Nuclidium AG is a clinical-stage biotechnology company headquartered in Basel, Switzerland with an R&D subsidiary in Munich, Germany, founded in 2017 by CEO Dr. Leila Jaafar-Thiel. The company develops copper-based radiopharmaceuticals for cancer diagnosis and therapy, built on its proprietary CuTrace™ platform which pairs Copper-61 (a 3.3-hour half-life positron emitter for PET diagnostics) with Copper-67 (a 2.58-day half-life beta-emitter for therapy) on the same targeting ligand, enabling true theranostics with identical biodistribution between diagnostic and therapeutic agents. Its pipeline comprises four programs: NU101/NuriPro (PSMA-targeted, metastatic castration-resistant prostate cancer), NU201/TraceNET (SSTR2 antagonist, metastatic breast cancer and neuroendocrine tumors), and Kalios (FAP inhibitor, breast and lung cancer), with Phase 1/2 results reported in 2025 and Phase 1/2a therapeutic trials planned for 2026.

The business model is pre-commercial: revenue is expected to be generated through sales of 61Cu-based diagnostic PET imaging agents and 67Cu-based therapeutic radiopharmaceuticals to hospital nuclear medicine departments, supplemented by licensing/royalty arrangements and a manufacturing/supply network. To de-risk commercialization and global distribution, Nuclidium has built a multi-region production footprint — cyclotron-based 61Cu production through PharmaLogic in the US and LinaThera in Medical Valley Forchheim, Germany — and entered a strategic partnership with Guerbet for manufacturing, clinical trial support and commercialization. The company raised approximately CHF 105 million (EUR ~115 million) in Series B financing (July 2025 plus May 2026 extension) from a syndicate including Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, Neva SGR and the EIB co-investment facility Aurea, supplemented by grants from Innosuisse and the European Innovation Council. Its go-to-market is enterprise field sales targeting major hospital systems and academic medical centers with nuclear medicine departments.

Nuclidium firmographics

Firmographics
Name
Nuclidium
Legal name
Nuclidium AG
Website
https://nuclidium.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Nuclidium AG is a clinical-stage Swiss radiopharmaceutical company developing copper-based theranostics (Copper-61 diagnostics and Copper-67 therapeutics on the CuTrace™ platform) for cancer indications including prostate, breast and neuroendocrine tumors, targeting hospital nuclear medicine departments globally.
Ownership category
akta.pro rank

Nuclidium industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Copper radiopharmaceuticals
  • Cancer theranostics
  • Targeted radiotherapy
  • PET imaging agents
  • Precision oncology drugs

Where Nuclidium is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

Nuclidium business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Radiopharmaceutical Products: NUCLIDIUM develops and commercializes copper-based radiopharmaceuticals for cancer diagnosis and treatment. Revenue will be generated through sales of diagnostic PET imaging agents (61Cu-based) and therapeutic radiopharmaceuticals (67Cu-based) to hospitals and nuclear medicine centers.
  2. Licensing and Partnership Agreements: Strategic partnerships with companies like Guerbet and PharmaLogic for manufacturing, distribution, and clinical development support. May include milestone payments and royalties from licensed technology.
  3. Manufacturing and Supply Network: Revenue generated through global production and manufacturing network for diagnostics and therapeutics, serving hospital workflows with copper-based radiopharmaceuticals.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Nuclidium product offering

Product offering

Core offering

Nuclidium AG is a clinical-stage biotechnology company that develops copper-based radiopharmaceutical theranostics for cancer diagnosis and treatment. Using its proprietary CuTrace™ platform, the company pairs Copper-61 (diagnostic) with Copper-67 (therapeutic) on identical tumor-targeting molecules, enabling true theranostic pairs for prostate, breast, neuroendocrine, and FAP-expressing tumors. Products are designed for cyclotron-based production without nuclear reactors and are supplied to hospitals and nuclear medicine centers globally.

Product overview

Nuclidium is a clinical-stage radiopharmaceutical company pioneering next-generation copper-based radiotheranostics. The company's CuTrace platform enables true theranostics by combining copper isotopes (Copper-61 for diagnostics and Copper-67 for therapeutics) with tumor-specific targeting molecules. The pipeline includes: NU101 (NuriPro) for PSMA-positive metastatic castration-resistant prostate cancer, NU201 for metastatic breast cancer, TraceNET for neuroendocrine tumors, and Kalios for FAP-expressing epithelial tumors. Individual products include 61Cu-NuriPro and 61Cu-TraceNET diagnostics, along with their corresponding 67Cu therapeutics. The company operates in Switzerland and Germany with manufacturing partnerships in Europe and North America.

Differentiator

Problem solved

Functional benefit

Brands

  • CuTrace: Proprietary technology platform utilizing copper radionuclides combined with tumour-specific molecules for targeted radiotherapy and diagnostics
  • NuriPro
  • TraceNET
  • Kalios
  • NU101
  • NU201

Products and services

  • NU101 / NuriPro
  • NU201 / TraceNET
  • Kalios
  • 61Cu-NuriPro (61Cu-NODAGA-PSMA I&T)
  • 61Cu-TraceNET ([61Cu]Cu-NODAGA-LM3)
  • 67Cu-NuriPro
  • 67Cu-TraceNET

Quantifiable outcome

  • 61Cu-NuriPro PET visualized additional lesions in 50% of patients not seen with 18F-piflufolastat (FDA-approved standard of care)
  • +4 more outcomes

Companies that use Nuclidium

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Nuclidium technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Nuclidium partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered major and core.

  • Hoag Memorial Hospital PresbyterianmajorStrategic or Co-development Partner · 21 October 2024Phase 1 clinical trial site for 61Cu-NuriPro™ diagnostic in PSMA-positive prostate cancer patients. Dr. Gary Ulaner serves as Principal Investigator. Trial conducted at Hoag Molecular Imaging and Therapy Clinic, Newport Beach, California.
  • Medical Valley Center ForchheimcoreStrategic or Co-development Partner · 13 June 2024Collaboration partner in Oberfrankenstiftung-funded project for production facility and clinical development of radionuclide therapies in Bavaria.
  • Klinikum BayreuthcoreStrategic or Co-development Partner · 13 June 2024Clinical collaboration partner in Oberfrankenstiftung-funded project for radionuclide therapy production and development.
  • Erlangen University HospitalcoreStrategic or Co-development Partner · 13 June 2024Academic partner in Oberfrankenstiftung-funded project for clinical development of radionuclide therapies.
  • GuerbetmajorStrategic or Co-development Partner · 22 May 2024Strategic partnership for advancement of NUCLIDIUM's copper-based radiotheranostics. Guerbet provides access to global diagnostic imaging expertise, manufacturing network, and clinical trial capabilities. François Nicolas (SVP R&D) joined NUCLIDIUM Board as observer. Guerbet made strategic, non-exclusive investment.
  • LinaTheramajorStrategic or Co-development Partner · 2 February 2024Partnership for building state-of-the-art integrated manufacturing facility in Medical Valley Forchheim. LinaThera produces medical radionuclides in modularly expandable accelerator facility without nuclear reactors. Project supported by Oberfrankenstiftung funding (€400,000).
  • PharmaLogic HoldingsmajorChannel Partner/ Reseller/ Distributor · 15 May 2023Strategic collaboration for production and clinical supply of 61Cu in the United States. PharmaLogic manufactures radiopharmaceuticals at their facilities including Los Angeles, CA. NUCLIDIUM provides scientific know-how and proprietary technology. First product batch manufactured in 2023.
  • University Hospital BaselmajorStrategic or Co-development Partner · 21 March 2023Clinical collaboration for Phase 1 trial with TraceNET™ in neuroendocrine tumors. NETRF Investigator Award shared between NUCLIDIUM and USB. Prof. Melpomeni Fani leads as PI. Clinical-scale production process established at USB.
  • Neuroendocrine Tumors Research Foundation (NETRF)coreOthers · 21 March 2023NETRF Investigator Award recipient for Phase 1 trial with TraceNET™ in neuroendocrine tumors. Award aims to support innovative research to improve NET patient care.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Nuclidium competitors and assessment

Company assessment

Direct peers

  • Curium: Curium is a global radiopharmaceutical company producing diagnostic and therapeutic nuclear medicines, including PET tracers. Comparable as both a competitor and potential commercial partner for radiopharma distribution.
  • Telix Pharmaceuticals: Telix commercializes Illuccix (Ga-68 PSMA-11) for PSMA PET imaging and is developing therapeutic radiopharmaceuticals. Direct competitor across the PSMA theranostic landscape with commercial-stage products.
  • Point Biopharma (acquired by Eli Lilly): Point Bio developed Lu-177 PSMA radioligand therapies for mCRPC and was acquired by Eli Lilly for $1.4B in 2024. Highly comparable as a PSMA radioligand developer and a benchmark for the exit opportunity Nuclidium's NU101 could pursue.
  • ITM Isotope Technologies Munich: ITM is a radiopharmaceutical company developing therapeutic and diagnostic radioisotope-based products, including Lu-177-based compounds. Competes in the precision oncology radiopharma space with similar production and distribution infrastructure.
  • Lantheus Holdings: Lantheus commercializes Pylarify (18F-piflufolastat), the FDA-approved PSMA PET imaging agent that Nuclidium's 61Cu-NuriPro demonstrated superiority over in Phase 1 trials. Direct competitor in the diagnostic PSMA imaging market.
  • Ariceum Therapeutics: Ariceum develops SSTR2 antagonist-based radiopharmaceuticals (acquired from Ipsen), directly overlapping with Nuclidium's TraceNET SSTR2 program. Notably, Nuclidium's CMO Ben Pais previously led clinical development at Ariceum.

Broad incumbents

  • Novartis (Pluvicto/Locametz): Novartis commercializes Pluvicto (Lu-177 PSMA-617) and Locametz for mCRPC, directly competing with Nuclidium's NU101 program. As the established radioligand therapy leader with approved products and global launch infrastructure, Novartis represents the primary competitive benchmark.
  • Bayer (radiopharma via Algeta/Lantheus partnership): Bayer has invested in radiopharmaceuticals including Xofigo (Ra-223) and partnerships targeting PSMA and other radioligand therapies. As a broad incumbent pharma with significant radiopharma ambitions, Bayer represents both competitor and potential acquirer.
  • Bracco Imaging: Bracco is an established diagnostic imaging company with a growing radiopharmaceutical portfolio. Overlaps with Nuclidium in molecular imaging agents and represents a potential commercial partner or acquirer for the diagnostic pipeline.

Emerging players

  • Radiopharm Theranostics: Radiopharm Theranostics is a clinical-stage radiopharma developing multiple radiotheranostic assets for oncology, with similar stage and pipeline breadth to Nuclidium. Directly comparable as a peer emerging radiotheranostic platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Nuclidium social profiles

Digital presence

Nuclidium financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nuclidium leadership team

Management profile

Number of profiles

Profiles14 records

Nuclidium funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nuclidium M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nuclidium

What does Nuclidium do?

Nuclidium AG is a clinical-stage biotechnology company that develops copper-based radiopharmaceutical theranostics for cancer diagnosis and treatment. Using its proprietary CuTrace™ platform, the company pairs Copper-61 (diagnostic) with Copper-67 (therapeutic) on identical tumor-targeting molecules, enabling true theranostic pairs for prostate, breast, neuroendocrine, and FAP-expressing tumors. Products are designed for cyclotron-based production without nuclear reactors and are supplied to hospitals and nuclear medicine centers globally.

Is Nuclidium a public or private company?

Nuclidium is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nuclidium founded?

Nuclidium was founded in 2017. It employs 11 to 50 people.

Where is Nuclidium based?

Nuclidium is headquartered in Basel, Switzerland, in the Europe region.

How does Nuclidium make money?

Three revenue lines are on record. Radiopharmaceutical Products are the primary driver. The others are licensing and Partnership Agreements and manufacturing and Supply Network.

Who are Nuclidium's main competitors?

Direct peers on record are Curium, Telix Pharmaceuticals, Point Biopharma (acquired by Eli Lilly), ITM Isotope Technologies Munich, Lantheus Holdings and Ariceum Therapeutics. Broad incumbents are Novartis (Pluvicto/Locametz), Bayer (radiopharma via Algeta/Lantheus partnership) and Bracco Imaging. Radiopharm Theranostics is listed as an emerging player.

Does Nuclidium have an API?

No public API is recorded for Nuclidium.

What industry is Nuclidium in?

Nuclidium's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Imaging Technology NewsNuclidium, NorthStar Medical Team Up to Advance Copper-67 Radiotheranostic Oncology PipelineNuclidium AG and NorthStar Medical announced a long-term partnership where NorthStar will produce Copper-67 and provide radiopharmaceutical manufacturing services for Nuclidium's therapeutic programs. The collaboration supports Nuclidium's lead programs NU101 for mCRPC and NU201 for mBC, aiming to expand global patient access to precision radiopharmaceutical therapies.The Pharma LetterNuclidium signs long-term copper-67 supply and manufacturing deal with NorthStarNuclidium signed a long-term partnership with NorthStar Medical Technologies, which will produce copper-67 and provide radiopharmaceutical manufacturing services for Nuclidium's therapeutic programs. Copper-67 is the therapeutic isotope in Nuclidium's radiotheranostic programs, paired with copper-61 for diagnostics. The company cites advantages including streamlined manufacturing and reduced waste.Business & FinancialNUCLIDIUM And Northstar Enter Long-Term Strategic Partnership To Advance NUCLIDIUM's Copper-67 Radiotheranostic Oncology PipelineNUCLIDIUM and NorthStar announced a long-term partnership to produce Copper-67 and provide radiopharmaceutical manufacturing for NUCLIDIUM's oncology programs. The collaboration spans clinical development through commercialization, leveraging NorthStar's vertically integrated campus. NUCLIDIUM's lead programs NU101 and NU201 for prostate and breast cancer are advancing into Phase 1/2 trials.GlobeNewswireNUCLIDIUM and NorthStar Enter Long-term Strategic Partnership to Advance NUCLIDIUM’s Copper-67 Radiotheranostic Oncology PipelineNUCLIDIUM and NorthStar announced a long-term partnership where NorthStar will produce Copper-67 and provide radiopharmaceutical manufacturing for NUCLIDIUM's oncology programs. The collaboration supports lead programs NU101 for prostate cancer and NU201 for breast cancer, with clinical studies planned in coming months.Business Wire BlogNUCLIDIUM and NorthStar Enter Long-term Strategic Partnership to Advance NUCLIDIUM’s Copper-67 Radiotheranostic Oncology PipelineNUCLIDIUM and NorthStar announced a long-term strategic partnership to produce Copper-67 and provide radiopharmaceutical manufacturing services for NUCLIDIUM's oncology pipeline. The collaboration supports lead programs NU101 for metastatic prostate cancer and NU201 for breast cancer, with clinical studies planned in coming months.TradingViewNUCLIDIUM AG Signs Long-Term Cu-67 Supply And Manufacturing DealNUCLIDIUM AG signed a long-term partnership with NorthStar for Copper-67 production and radiopharmaceutical manufacturing to support its oncology programs from clinical development through commercialization. The deal covers lead programs NU101 and NU201 for mCRPC and mBC, with U.S.-based cGMP capacity. It secures supply for upcoming trials and reduces execution risk.FinancialContent Business PageNUCLIDIUM and NorthStar Enter Long-term Strategic Partnership to Advance NUCLIDIUM’s Copper-67 Radiotheranostic Oncology PipelineNUCLIDIUM and NorthStar announced a long-term partnership where NorthStar will produce Copper-67 and provide radiopharmaceutical manufacturing for NUCLIDIUM's oncology programs. The collaboration supports lead programs NU101 for metastatic prostate cancer and NU201 for breast cancer, aiming to advance clinical development and commercialization.TradingViewNUCLIDIUM and NorthStar Enter Long-term Strategic Partnership to Advance NUCLIDIUM’s Copper-67 Radiotheranostic Oncology PipelineNUCLIDIUM and NorthStar announced a long-term partnership where NorthStar will produce Copper-67 and provide radiopharmaceutical manufacturing services for NUCLIDIUM's oncology programs. The collaboration supports lead programs NU101 for metastatic prostate cancer and NU201 for breast cancer, with clinical studies planned in coming months.startupticker.chFrom positive clinical developments to support offers for biotech startupsMuvon Therapeutics, Neurosterix, and Nuclidium advanced clinical studies for SUI, schizophrenia, and prostate cancer, respectively. Muvon reported positive interim results from its Phase 2 trial, Neurosterix completed its Phase 1 study, and Nuclidium imaged its first patient in Phase 2. Swiss Innovation Park Basel will open a new lab for startups in January 2027.SWI swissinfo.chNuclidium CEO: ‘Our challenge remains the demonstration of clinical efficacy and utility’Nuclidium raised over CHF100 million in Series B funding to develop copper-based radiopharmaceuticals for cancer diagnosis and therapy. CEO Leila Jaafar said the company must first demonstrate clinical efficacy and utility before bringing products to market. She also cited supply chain reliability as an immediate challenge.